Related Experiment Videos
Antisense oligonucleotides: promise and reality.
1College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
Annual Review of Pharmacology and Toxicology
|March 27, 2001
Summary
Antisense oligonucleotides, like phosphorothioate oligonucleotides, can inhibit gene expression. Interpreting experimental data from these bioactive molecules, particularly for bcl-2 in tumor cells, requires careful consideration of multiple mechanisms.
Area of Science:
- Molecular Biology
- Gene Regulation
- Oligonucleotide Therapeutics
Background:
- Antisense oligonucleotides (ASOs) are established tools for gene silencing.
- Phosphorothioate oligonucleotides offer enhanced nuclease resistance and are widely used in research and clinical trials.
- The bioactivity of ASOs suggests potential for multiple gene inhibition mechanisms.
Purpose of the Study:
- To review challenges in interpreting experimental data from antisense oligonucleotides.
- To discuss mechanisms of gene silencing by ASOs.
- To highlight issues related to bcl-2 inhibition in tumor cells.
Main Methods:
- Literature review of antisense oligonucleotide applications.
- Analysis of gene silencing mechanisms.
- Case study on bcl-2 inhibition in cancer.
Main Results:
- Phosphorothioate oligonucleotides are common but highly bioactive.
- Multiple mechanisms may contribute to gene expression inhibition by ASOs.
- Interpreting ASO experimental data can be complex.
Conclusions:
- Careful interpretation of experimental data is crucial when using antisense oligonucleotides.
- Understanding diverse mechanisms is key for effective ASO application, especially for targeting bcl-2 in tumors.